Patents Assigned to Merck
  • 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives
    Publication number: 20110257173
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R3?, R4 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: November 26, 2009
    Publication date: October 20, 2011
    Applicant: MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA
    Publication number: 20110253935
    Abstract: The present invention relates to liquid-crystalline compounds having two fluorinated biphenyl units, a terminal trifluoromethyl or trifluoromethoxy group and a —CF2O— bridge between the two fluorinated biphenyl units. The invention also relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.
    Type: Application
    Filed: April 14, 2011
    Publication date: October 20, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCRANKTER HAFTUNG
    Inventors: Axel JANSEN, Helmut Haensel, Malgorzata Rillich
  • 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES
    Publication number: 20110257170
    Abstract: This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.
    Type: Application
    Filed: September 30, 2009
    Publication date: October 20, 2011
    Applicant: MERCK SERONO SA
    Inventors: Vincent Pomel, Pascale Gaillard, Gwenaelle Desforges, Anna Quattropani, Cyril Montagne
  • COMPOSITIONS AND METHODS FOR TREATING GROWTH HORMONE DEFICIENCY
    Publication number: 20110257098
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: November 25, 2009
    Publication date: October 20, 2011
    Applicant: MERCK SERONO S.A.
    Inventors: Marianne Tuefferd, Jérôme Dauvillier, Arnaud Delaye, Sonia Schnieper-Samec
  • LIQUID-CRYSTAL DISPLAY
    Publication number: 20110255048
    Abstract: The present invention relates to liquid-crystal (LC) media for use in LC displays of the PS (polymer stabilised) or PSA (polymer sustained alignment) type.
    Type: Application
    Filed: November 26, 2009
    Publication date: October 20, 2011
    Applicant: Merck Patent Gesellschaft MIT Beschraenkter Haftung
    Inventors: Achim Goetz, Melanie Klasen-Memmer, Stepham Derow
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20110257181
    Abstract: Compounds of the formula (I), in which Y, R1, R2, R3 and R3? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: November 24, 2009
    Publication date: October 20, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Organic semiconductor solutions
    Patent number: 8038903
    Abstract: The present invention relates to liquid compositions, in particular solutions, of at least one organic semiconductor which emits light from the triplet state, in an organic solvent or solvent mixture, which are characterised in that the content of certain compounds is below a certain limit value, and to the use thereof for the production of layers of the organic semiconductors on substrates, in particular for the electronics industry.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: October 18, 2011
    Assignee: Merck Patent GmbH
    Inventors: Hubert Spreitzer, Susanne Heun, Neil Tallant
  • Antidiabetic bicyclic compounds
    Patent number: 8039484
    Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 18, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
  • Materials for organic electroluminescent devices
    Patent number: 8039126
    Abstract: The present invention relates to triarylamines which are substituted by defined groups. These compounds can be used for producing organic electroluminescent devices.
    Type: Grant
    Filed: March 3, 2007
    Date of Patent: October 18, 2011
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stössel, Holger Heil, Arne Buesing
  • Machine-readable security element for security products
    Patent number: 8039094
    Abstract: The invention relates to a machine-readable security element for security products, containing at least one particulate substance that has electroluminescent properties and a transparent, electrically conductive pigment. Also disclosed are a printing ink for producing such a security element and a security product comprising said security element.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: October 18, 2011
    Assignees: Merck Patent GmbH, Bundesdruckerei GmbH
    Inventors: Burkhard Krietsch, Matthias Kuntz, Oliver Muth, Manfred Paeschke, Jakob Kuen
  • CGRP receptor antagonists
    Patent number: 8039460
    Abstract: Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: October 18, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher S. Burgey, Daniel V. Paone, Anthony W. Shaw, Diem N. Nguyen, Zhengwu J. Deng, Theresa M. Williams, Joseph P. Vacca, Craig M. Potteiger, Harold G. Selnick
  • PIGMENT GRANULES
    Publication number: 20110251303
    Abstract: Pigment granules comprise one or more flake-form effect pigments, polymer particles or polymer particle mixtures, adhesion promoters, antioxidants and optionally additives. A process for the preparation of pigment granules comprises mixing one or more flake-form effect pigments, one or more polymer particles, at least one adhesion promoter, at least one antioxidant and optionally one or more additives with one another simultaneously or successively. The pigment granules may be used for the pigmentation of powder coatings, plastics and for the preparation of masterbatches. The pigment granules may be employed as a mixture with plastic powders or as a mixture with plastic granules for use in masterbatch applications.
    Type: Application
    Filed: December 18, 2009
    Publication date: October 13, 2011
    Applicant: Merck Patent GmbH
    Inventors: Thomas Rathschlag, Carsten Griessmann
  • Anthra[2,3-b]benzo[d]thiophene Derivatives and their Use as Organic Semiconductors
    Publication number: 20110248220
    Abstract: The invention relates to novel anthra[2,3-b]benzo[d]thiophene derivatives, methods of their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these derivatives.
    Type: Application
    Filed: November 27, 2009
    Publication date: October 13, 2011
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Steven Tierney, Changsheng Wang, William Mitchell
  • METHOD OF DESIGNING siRNAS FOR GENE SILENCING
    Publication number: 20110250591
    Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.
    Type: Application
    Filed: May 4, 2011
    Publication date: October 13, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Wei Ge, Guy L. Cavet
  • LIQUID-CRYSTAL MEDIUM
    Publication number: 20110248216
    Abstract: The invention relates to a liquid-crystalline medium having negative dielectric anisotropy which comprises at least one compound of the formula I in which R1, R1* and a have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PS-VA, PALC, FFS or IPS effect.
    Type: Application
    Filed: December 17, 2009
    Publication date: October 13, 2011
    Applicant: MERCK PATENT GMBH
    Inventors: Melanie Klasen-Memmer, Matthias Bremer, Konstantin Schneider, Detlef Pauluth
  • BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS
    Publication number: 20110251207
    Abstract: In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: October 6, 2009
    Publication date: October 13, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier, Jie Wu, Junying Zheng, Younong Yu, Jianhua Chao, Walter S. Won, Ashwin U. Rao, Rongze Kuang, Pauline C. Ting, Xianhai Huang, Ning Shao, Adandan Palani, Michael Y. Berlin, Robert G. Aslanian
  • 2,5-Disubstituted Piperidine Orexin Receptor Antagonists
    Publication number: 20110251237
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 13, 2011
    Applicant: MERCK SHARP & DOHME CROP.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
  • Inhibitor of vascular endothelial cell growth factor
    Patent number: 8034772
    Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: October 11, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Jr.
  • Opaque plastics
    Patent number: 8034864
    Abstract: The present invention relates to opaque plastics comprising effect pigments which are distinguished by the fact that they have high gloss and virtually no visible or no visible flow lines.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: October 11, 2011
    Assignee: Merck Patent GmbH
    Inventors: Manfred Kieser, Markus Schum
  • PACKAGING FOR OXYGEN-SENSITIVE PHARMACEUTICAL PRODUCTS
    Publication number: 20110240511
    Abstract: The present invention relates to packaging and containers for oxygen-sensitive pharmaceutical products, or oxygen- and moisture-sensitive pharmaceutical products. More particularly, the invention relates to pharmaceutical packages comprising a blister pack with airflow channels and outlets, an oxygen scavenger, and, optionally, a desiccant, all of which are sealed inside an outer container having oxygen and moisture barrier properties.
    Type: Application
    Filed: December 2, 2009
    Publication date: October 6, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Matthew P. Bolton, Rey T. Chern, Arthur L. Jaeger, Matthew Moyer, Anthony P. Panarello